Neuren Pharmaceuticals Advances PMS Treatment Trials
Company Announcements

Neuren Pharmaceuticals Advances PMS Treatment Trials

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals is set to begin Phase 3 trials for NNZ-2591, a potential first-ever treatment for Phelan-McDermid syndrome (PMS), following a constructive FDA meeting. The trial will be a 13-week, randomized, double-blind study on children aged 3 to 12, with continuity in an open-label extension study until commercial launch. The company is finalizing efficacy endpoints with the FDA and proceeding with trial preparations, including site selection and drug manufacturing.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Updates Policy Amid Financial Growth
TipRanks Australian Auto-Generated NewsdeskNeuren’s DAYBUE Gains Canadian Approval, Expanding Market
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App